Abstract
Liquid next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA) has become a promising tool for the identification of driver mutations in non-small cell lung cancer (NSCLC). Whether liquid NGS performed immediately at the start of tumor workup could further enhance NSCLC patient survival is unclear.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
